Snapshot from Sep 13, 2026 at 07:00 UTC. For live data and tracking: View Live
Business product promotion

Precision BioLogic Promotes Hemostasis Diagnostics

Analysis based on 6 articles · First reported Aug 27, 2026 · Last updated Aug 27, 2026

Sentiment
10
Attention
1
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The event is a promotional and educational effort by Precision BioLogic, which may modestly raise its profile among hemostasis clinicians and researchers. It does not directly affect major market indices or the stock prices of large pharmaceutical companies, but could support demand for Precision BioLogic's diagnostic products as new hemophilia treatments advance.

Medical diagnostics Pharmaceuticals

Precision BioLogic Inc., a developer of hemostasis diagnostic products, and its subsidiaries Precision BioLogic — Affinity Biologicals and Precision BioLogic — George King Bio-Medical, are promoting their combined expertise in hemostasis diagnostics and research. The company highlighted its CRYOcheck Chromogenic Factor VIII assay, which is designed to accurately measure factor VIII in the presence of emerging hemophilia treatments such as Mim8, a bispecific antibody developed by Novo Nordisk. Interest has increased following Novo Nordisk's submission of Mim8 to the United States — Food and Drug Administration. Precision BioLogic exhibited at the ISTH 2026 congress in Paris, presented two scientific posters, showcased manufacturing capabilities at ADLM 2026, and engaged with the bleeding disorders community at the NBDF conference. The company aims to ensure coagulation labs are prepared for new therapies.

70 Precision BioLogic announced expanded utility
50 Precision BioLogic showcased manufacturing capabilities Association for Diagnostics & Laboratory Medicine
40 Precision BioLogic — George King Bio-Medical met with stakeholders National Bleeding Disorders Foundation
priv
Precision BioLogic is the central company promoting its CRYOcheck Chromogenic Factor VIII assay and related products. The event enhances its visibility and positions it to benefit from the adoption of new hemophilia therapies.
Importance 100.0 Sentiment 60.0
stock
Novo Nordisk's submission of Mim8 to the FDA is a key driver of interest in Precision BioLogic's assay. The event indirectly supports Novo Nordisk's hemophilia treatment pipeline by ensuring accurate diagnostic testing.
Importance 60.0 Sentiment 70.0
subs
Precision BioLogic — Affinity Biologicals, a subsidiary of Precision BioLogic, showcased its manufacturing capabilities at ADLM 2026, reinforcing its role in providing custom solutions for hemostasis research and diagnostics.
Importance 40.0 Sentiment 50.0
subs
Precision BioLogic — George King Bio-Medical, another subsidiary, engaged with the bleeding disorders community at the NBDF conference, highlighting the importance of plasma donation and strengthening its ties to patients and advocates.
Importance 40.0 Sentiment 50.0
govactor
The FDA is the regulatory body reviewing Novo Nordisk's Mim8 submission. Its decision will influence the adoption of new hemophilia treatments and the demand for associated diagnostic assays.
Importance 30.0 Sentiment 0.0
per
Paul Empey, President and CEO of Precision BioLogic, is quoted in the press release, articulating the company's strategy and commitment to supporting coagulation labs.
Importance 30.0 Sentiment 0.0
ngo
ISTH hosted the congress where Precision BioLogic exhibited and presented research, providing a platform to reach hemostasis professionals.
Importance 30.0 Sentiment 0.0
ngo
ADLM hosted the conference where Precision BioLogic showcased its manufacturing capabilities, contributing to its visibility in the diagnostics community.
Importance 20.0 Sentiment 0.0
ngo
NBDF's conference allowed Precision BioLogic — George King Bio-Medical to engage with patients and advocates, reinforcing the importance of plasma donation and community relations.
Importance 20.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.